Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 2, Pages 1050-1052Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01897-12
Keywords
-
Categories
Funding
- CSIR, India [NWP0035]
- ICMR, India
- South African Medical Research Council
- K-RITH collaborative grant (Howard Hughes Medical Institute)
- K-RITH collaborative grant (University of KwaZulu-Natal)
Ask authors/readers for more resources
Inhalable clofazimine-containing dry powder microparticles (CFM-DPI) and native clofazimine (CFM) were evaluated for activity against Mycobacterium tuberculosis in human monocyte-derived macrophage cultures and in mice infected with a low-dose aerosol. Both formulations resulted in 99% killing at 2.5 mu g/ml in vitro. In mice, 480 mu g and 720 mu g CFM-DPI inhaled twice per week over 4 weeks reduced numbers of CFU in the lung by as much as log(10) 2.6; 500 mu g oral CFM achieved a log(10) 0.7 reduction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available